Abstract
Purpose of reviewAdvances in pharmacogenomics have paved the way for personalized medicine. The purpose of this review is to summarize the background, rationale, and evidence for pharmacogenomics in cardiovascular medicine.Recent findingsRandomized clinical trials have supported the role of a genotype-guided approach for antiplatelet therapy in patients with coronary artery disease undergoing percutaneous coronary interventions. Additionally, there is increasing evidence supporting the association of certain genetic variants and risk of statin associated muscle symptoms. Furthermore, germline genetic variation is being used as a biomarker to target patients with specific therapy.SummaryPharmacogenomics has the potential to improve patient care by providing the right drug to the right patient and could guide the identification of novel drug therapies for cardiovascular disease.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 207-214 |
| Number of pages | 8 |
| Journal | Current opinion in cardiology |
| Volume | 38 |
| Issue number | 3 |
| DOIs | |
| State | Published - May 1 2023 |
Keywords
- cardiovascular disease
- genotype
- pharmacogenomics
- phenotype
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine